Asset Management

UK funds surged more than £2bn on back of vaccine buzz

Days before Pzifer-BioNTech's vaccine breakthrough, funds posted net outflows of £389m, reversed in the days after with equity funds pulling in £1.4bn in new money

A close-up of a COVID-19 vaccine at Cardiff and Vale Therapy Centre. Before Pzifer-BioNTech's vaccine breakthrough, equity funds posted net outflows, which were reversed in the five days after the vaccine announcement, with equity funds pulling in 1.4bn of new money.
A close-up of a COVID-19 vaccine at Cardiff and Vale Therapy Centre. Before Pzifer-BioNTech's vaccine breakthrough, equity funds posted net outflows, which were reversed in the five days after the vaccine announcement, with equity funds pulling in 1.4bn of new money. Photo: Getty Images

Investors funnelled more than £2bn into UK-based funds during November following successful developments on Covid-19 vaccines, with active managers registering their biggest haul in more than five years.

Data from Calastone, which tracks money entering and leaving funds from financial advisers, fund supermarkets and wealth managers, show funds on sale to UK investors garnered a net £2.3bn during November — the second highest month on record for inflows. The previous high was recorded in April, when global markets were buoyed by the various support packages announced by governments and central banks.

WSJ Logo